Skip to main content
. Author manuscript; available in PMC: 2018 Feb 1.
Published in final edited form as: J Nerv Ment Dis. 2017 Feb;205(2):154–160. doi: 10.1097/NMD.0000000000000563

Table 4.

Changes in clinical outcomes

Measure Baseline Post-Treatment Analysis (Pre to Post) Effect Size*

Mean SD Mean SD F Df p
CAPS Severity 87.45 18.92 34.57 17.71 36.61 1, 9.0 <.001 2.79
 Cluster B 25.18 7.05 7.00 4.69 46.17 1, 9.50 <.001 2.58
 Cluster C 34.45 9.70 13.00 10.46 19.71 1, 16.0 <.001 2.21
 Cluster D 27.81 4.91 14.57 5.44 28.64 1, 16.0 <.001 2.70
PCL Severity 58.36 12.00 31.29 11.56 30.88 1, 6.80 .001 2.26
 Cluster B 17.00 3.58 8.86 3.24 24.92 1, 13.9 <.001 2.27
 Cluster C 22.45 7.01 12.43 5.26 19.43 1, 6.70 .003 1.43
 Cluster D 18.91 2.88 12.16 5.04 35.38 1, 14.5 <.001 2.34
BDI-II Severity 26.09 13.11 14.00 14.69 10.98 1, 16.0 .004 0.92
 Cognitive 16.81 9.21 8.00 9.45 12.70 1, 15.9 .003 0.96
 Somatic 9.30 4.57 6.00 5.26 4.57 1, 14.8 .050 0.72
STAXI-2 Anger Expression Index 41.44 13.73 31.71 12.83 4.73 1, 13.4 .048 0.71

Note: CAPS-the Clinician Administered PTSD Scale; PCL- the PTSD Checklist; Cluster B-re-experiencing symptoms, Cluster C-avoidance/numbing symptoms, Cluster D-hyperarousal symptoms; BDI-II- Beck Depression Inventory, second edition; STAXI-2 Anger Expression Index- State-Trait Anger Expression Inventory-2.

*

Cohen’s d = (Mpre−Mpost)/s; cutoffs scores are: 0.2—small, 0.5—medium, and 0.8—large